Kyntra Bio, Inc.
KYNB
$7.94
-$0.10-1.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 178.79% | -6.88% | -107.09% | 2,738.91% | -263.89% |
| Total Depreciation and Amortization | -14.29% | -12.50% | -95.83% | -13.12% | -32.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3,006.58% | 42.42% | 101.71% | -1,963.00% | -33.25% |
| Change in Net Operating Assets | 5,115.93% | 105.58% | 96.98% | -1,001.18% | 414.77% |
| Cash from Operations | 71.26% | 24.23% | -892.31% | -114.56% | 366.42% |
| Capital Expenditure | -- | -- | 100.00% | 30.77% | 18.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 6,756.67% | -100.94% | -92.89% | -- | -- |
| Other Investing Activities | 344.41% | 105.30% | -1,815.09% | -- | -- |
| Cash from Investing | 485.59% | 105.84% | -159.33% | 670,561.54% | 18.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 99.99% | -2,685,166.67% | 160.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 28.57% | 12.50% | 33.33% | 0.00% | 67.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | 100.00% |
| Cash from Financing | 28.57% | 50.00% | 99.98% | -954,533.33% | 89.77% |
| Foreign Exchange rate Adjustments | -3,100.00% | 102.04% | 96.12% | -228.64% | -30.28% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 225.49% | 84.49% | -3,656.86% | -113.68% | 239.16% |